Michael Burkes Brophy Sells 482 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 482 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $210.49, for a total value of $101,456.18. Following the completion of the sale, the chief financial officer directly owned 57,496 shares in the company, valued at approximately $12,102,333.04. The trade was a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $64,528.08.
• On Wednesday, April 29th, Michael Burkes Brophy sold 3,070 shares of Natera stock. The shares were sold at an average price of $193.74, for a total value of $594,781.80.
• On Monday, April 27th, Michael Burkes Brophy sold 1,993 shares of Natera stock. The shares were sold at an average price of $204.14, for a total transaction of $406,851.02.
• On Tuesday, March 10th, Michael Burkes Brophy sold 785 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $160,242.05.

Natera Stock Performance

NASDAQ:NTRA opened at $215.09 on Thursday. The stock has a market capitalization of $30.61 billion, a PE ratio of -140.58 and a beta of 1.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The company has a fifty day moving average of $202.02 and a two-hundred day moving average of $214.75.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same quarter last year, the business earned ($0.41) earnings per share. Research analysts forecast that Natera, Inc. will post -1.71 earnings per share for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly results beat expectations: Natera reported $0.35 EPS and $665.5M revenue, well above consensus — this outperformance supports upside in the stock. Earnings and company page
• Positive Sentiment: Analyst support is generally constructive: several firms have recent Buy/Outperform notes and the consensus target (~$253.47) sits above current levels, which can attract momentum buyers. Analyst coverage
• Positive Sentiment: Institutional inflows noted (new/expanded stakes by firms such as Robinhood Asset Management and JPMorgan), indicating larger investors remain interested in the growth story. Institutional holdings
• Neutral Sentiment: Multiple insiders (CEO Steven Chapman, CFO Michael Brophy, John Fesko, Solomon Moshkevich) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vesting awards; these are scheduled, limited reductions rather than opportunistic dumps. Insider trades summary
• Negative Sentiment: Fundamentals still show profitability headwinds: Natera reports a negative net margin and negative ROE, and analysts model a negative EPS for the fiscal year, which leaves valuation and path‑to‑sustained profitability as open risks. Financial metrics and estimates

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC increased its position in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth raised its stake in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Natera in the 2nd quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera in the 2nd quarter worth approximately $558,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NTRA. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Morgan Stanley lowered their price target on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Robert W. Baird increased their price objective on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. William Blair assumed coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company raised their price objective on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.